This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celgene Corporation Announces 2014 Financial Outlook And Preliminary 2013 Results

Celgene Corporation (NASDAQ:CELG) provided its preliminary 2013 results and financial outlook for 2014 and beyond at the 32 nd Annual J.P. Morgan Healthcare Conference. In 2013, total revenue is expected to be approximately $6.5 billion and total net product sales are expected to be $6.4 billion. Adjusted diluted earnings per share (EPS) is expected to be approximately $5.96. Based on U.S. Generally Accepted Accounting Principles (GAAP), diluted EPS is expected to be in the range of $3.37 to $3.39. In 2014, total net product sales are expected to be $7.3 billion to $7.4 billion, a 16 percent year-over-year increase. Adjusted diluted EPS is expected to be $7.00 to $7.20, a 19 percent year-over-year increase based on the mid-point of the range. On a GAAP basis, diluted EPS is expected to be in the range of $5.54 to $5.92.

“Our 2013 accomplishments and confidence in our core business position us for another year of outstanding execution across all financial metrics in 2014 as we launch our I&I franchise and anticipate achieving many other significant milestones,” said Bob Hugin, Celgene’s Chairman and Chief Executive Officer. “2013 momentum and confidence in our business model leads us to raise our 2015 and 2017 targets.”

Preliminary 2013 Financial Results Year-Over-Year (Unaudited)

  • Total net product sales are expected to be $6.4 billion, up 18 percent year-over-year
  • REVLIMID ®: $4,280 million, 14 percent year-over-year increase
  • ABRAXANE ®: $649 million, 52 percent year-over-year increase
  • POMALYST ®/IMNOVID ®: $305 million
  • Adjusted operating margin is expected to be approximately 48.4 percent for the full year, up 30 basis points (bps) year-over-year and includes the impact of $65 million in collaboration-related payments to partners. GAAP operating margin is expected to be approximately 27.9 percent, a decrease of 385 bps year-over-year, primarily due to increased upfront payments to collaboration partners in 2013
  • Adjusted 2013 diluted EPS is expected to be approximately $5.96, a 21 percent year-over-year increase. This includes a $0.13 per share negative impact from collaboration-related payments to partners. On a GAAP basis, diluted EPS is expected to be in the range of $3.37 to $3.39
  • For the fourth quarter of 2013 adjusted diluted EPS is expected to be approximately $1.51 which includes a $0.10 per share negative impact from collaboration-related payments to partners. On a GAAP basis, diluted EPS is expected to be in the range of $0.50 to $0.52

Certain activities involved in determining the audited results for the fiscal year ended December 31, 2013 are in process and could result in the final reported audited results being different from the unaudited results noted in this press release. Please see the attached Reconciliation of Estimated/Projected GAAP to Adjusted Measures for further information.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs